A breakthrough urine test, GALEAS Bladder, has demonstrated a 92.2% sensitivity in detecting bladder cancer, offering a non-invasive diagnostic alternative.
The test analyzes specific biomarkers in urine, potentially reducing the need for invasive cystoscopy procedures for patients presenting with symptoms.
Medical experts suggest this could significantly improve early detection rates and streamline the clinical decision-making process for urologists.